Role of insulin-like growth factor-I in the treatment of painful small fiber predominant neuropathy

Anthony John Windebank, Eric James Sorenson, Richard Civil, Peter C. O'Brien

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Idiopathic, painful, small fiber predominant peripheral neuropathy is resistant to symptomatic treatment. Previous treatments have not been directed toward repairing the underlying deficit. Growth factors hold promise as agents to encourage axonal regrowth. In vitro, insulin-like growth factor-I (IGF-I) has been shown to prevent neuronal apoptosis, to increase axonal growth, and to support myelination. Using a double-blind, placebo-controlled design, 40 patients were randomized to treatment with recombinant human IGF-I (0.05 mg/kg twice daily by subcutaneous injection) or placebo for 6 months. There were no significant adverse events and minor adverse events occurred equally in both groups. The primary outcome measure was change in score on an analog pain scale. Secondary endpoints included quantitative sensory testing, quantitative autonomic testing, neuropathy impairment score, nerve conduction studies, and neuropathy symptom and change score. There was no significant difference in the primary endpoint between the two groups. Analysis of secondary endpoints and a global impression of improvement by patients and physicians did not show consistent differences between the groups. IGF-I was safe, but did not improve symptoms in this 6-month trial.

Original languageEnglish (US)
Pages (from-to)183-189
Number of pages7
JournalJournal of the Peripheral Nervous System
Volume9
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

Insulin-Like Growth Factor I
Placebos
Neural Conduction
Peripheral Nervous System Diseases
Pain Measurement
Subcutaneous Injections
Intercellular Signaling Peptides and Proteins
Therapeutics
Outcome Assessment (Health Care)
Apoptosis
Physicians
Growth
Small Fiber Neuropathy

Keywords

  • Axonal growth
  • Insulin-like growth factor-I
  • Nerve growth factor
  • Painful neuropathy
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Role of insulin-like growth factor-I in the treatment of painful small fiber predominant neuropathy. / Windebank, Anthony John; Sorenson, Eric James; Civil, Richard; O'Brien, Peter C.

In: Journal of the Peripheral Nervous System, Vol. 9, No. 3, 09.2004, p. 183-189.

Research output: Contribution to journalArticle

@article{6d289963f7f64819a56dd8e516da0016,
title = "Role of insulin-like growth factor-I in the treatment of painful small fiber predominant neuropathy",
abstract = "Idiopathic, painful, small fiber predominant peripheral neuropathy is resistant to symptomatic treatment. Previous treatments have not been directed toward repairing the underlying deficit. Growth factors hold promise as agents to encourage axonal regrowth. In vitro, insulin-like growth factor-I (IGF-I) has been shown to prevent neuronal apoptosis, to increase axonal growth, and to support myelination. Using a double-blind, placebo-controlled design, 40 patients were randomized to treatment with recombinant human IGF-I (0.05 mg/kg twice daily by subcutaneous injection) or placebo for 6 months. There were no significant adverse events and minor adverse events occurred equally in both groups. The primary outcome measure was change in score on an analog pain scale. Secondary endpoints included quantitative sensory testing, quantitative autonomic testing, neuropathy impairment score, nerve conduction studies, and neuropathy symptom and change score. There was no significant difference in the primary endpoint between the two groups. Analysis of secondary endpoints and a global impression of improvement by patients and physicians did not show consistent differences between the groups. IGF-I was safe, but did not improve symptoms in this 6-month trial.",
keywords = "Axonal growth, Insulin-like growth factor-I, Nerve growth factor, Painful neuropathy, Peripheral neuropathy",
author = "Windebank, {Anthony John} and Sorenson, {Eric James} and Richard Civil and O'Brien, {Peter C.}",
year = "2004",
month = "9",
doi = "10.1111/j.1085-9489.2004.09311.x",
language = "English (US)",
volume = "9",
pages = "183--189",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Role of insulin-like growth factor-I in the treatment of painful small fiber predominant neuropathy

AU - Windebank, Anthony John

AU - Sorenson, Eric James

AU - Civil, Richard

AU - O'Brien, Peter C.

PY - 2004/9

Y1 - 2004/9

N2 - Idiopathic, painful, small fiber predominant peripheral neuropathy is resistant to symptomatic treatment. Previous treatments have not been directed toward repairing the underlying deficit. Growth factors hold promise as agents to encourage axonal regrowth. In vitro, insulin-like growth factor-I (IGF-I) has been shown to prevent neuronal apoptosis, to increase axonal growth, and to support myelination. Using a double-blind, placebo-controlled design, 40 patients were randomized to treatment with recombinant human IGF-I (0.05 mg/kg twice daily by subcutaneous injection) or placebo for 6 months. There were no significant adverse events and minor adverse events occurred equally in both groups. The primary outcome measure was change in score on an analog pain scale. Secondary endpoints included quantitative sensory testing, quantitative autonomic testing, neuropathy impairment score, nerve conduction studies, and neuropathy symptom and change score. There was no significant difference in the primary endpoint between the two groups. Analysis of secondary endpoints and a global impression of improvement by patients and physicians did not show consistent differences between the groups. IGF-I was safe, but did not improve symptoms in this 6-month trial.

AB - Idiopathic, painful, small fiber predominant peripheral neuropathy is resistant to symptomatic treatment. Previous treatments have not been directed toward repairing the underlying deficit. Growth factors hold promise as agents to encourage axonal regrowth. In vitro, insulin-like growth factor-I (IGF-I) has been shown to prevent neuronal apoptosis, to increase axonal growth, and to support myelination. Using a double-blind, placebo-controlled design, 40 patients were randomized to treatment with recombinant human IGF-I (0.05 mg/kg twice daily by subcutaneous injection) or placebo for 6 months. There were no significant adverse events and minor adverse events occurred equally in both groups. The primary outcome measure was change in score on an analog pain scale. Secondary endpoints included quantitative sensory testing, quantitative autonomic testing, neuropathy impairment score, nerve conduction studies, and neuropathy symptom and change score. There was no significant difference in the primary endpoint between the two groups. Analysis of secondary endpoints and a global impression of improvement by patients and physicians did not show consistent differences between the groups. IGF-I was safe, but did not improve symptoms in this 6-month trial.

KW - Axonal growth

KW - Insulin-like growth factor-I

KW - Nerve growth factor

KW - Painful neuropathy

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=4944263592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4944263592&partnerID=8YFLogxK

U2 - 10.1111/j.1085-9489.2004.09311.x

DO - 10.1111/j.1085-9489.2004.09311.x

M3 - Article

C2 - 15363067

AN - SCOPUS:4944263592

VL - 9

SP - 183

EP - 189

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 3

ER -